Strong Medicine: The Cost of Prescription Drugs
One simple trick to bring down medical costs
August 2021
Script
This video is part of our Kite & Key Shorts series — easy to understand ... but hard to forget.
Why are prescription drugs so expensive?
Actually, hang on. Are prescription drugs expensive?
Not always.
In fact, 90% of prescriptions filled in the United States are generic,i and the average patient pays just $8 out-of-pocket for a generic prescription.ii
High prices mainly occur with new, cutting-edge treatments.
One reason? It costs an average of $2.6 billion to develop a single new drug.iii
The good news: even drugs that start out expensive rarely stay that way.
Just one generic competitor can lower prices nearly 40%,iv so the key to lowering drug costs is to get more generic drugs on the market.
One way to do that is to speed up the approval process.
The faster generic drugs get approved, the quicker they hit shelves and bring down prices.
High drug costs can be a real hardship, but we can lower them through competition and still preserve our access to life-saving medicine.
WHAT YOU NEED TO KNOW:
- 90% of prescriptions filled in the U.S. are generic — and the average patient pays only $8 out-of-pocket for them.
- The price of new drugs is high because the average cost of drug development is $2.6 billion.
- The introduction of just one generic competitor can lower drug prices by nearly 40%.
Sources
- “Generic Drugs” — U.S. Food and Drug Administration
- "IMS Health Study: U.S. Drug Spending Growth" — Business Wire
- “Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs” (Joseph A. DiMasi, Henry G. Grabowski, Ronald W. Hansen) — Journal of Health Economics
- “Generic Competition and Drug Prices” — U.S. Food and Drug Administration
Shownotes
SOUND: “Flying in the Clouds” (DP)
FOOTAGE: Adam Niescioruk (Unsplash)
CITED SOURCES AND NEWS OUTLETS ARE NOT AFFILIATED WITH THIS PRODUCTION.
Sources
- U.S. Food and Drug Administration
“Generic Drugs” - Business Wire
"IMS Health Study: U.S. Drug Spending Growth"
- Journal of Health Economics
“Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs” (Joseph A. DiMasi, Henry G. Grabowski, Ronald W. Hansen) - U.S. Food and Drug Administration
“Generic Competition and Drug Prices”
Delve Deeper
Bonus Content
More Videos
September 2023
Social Security’s Coming Reckoning
September 2023